Micell Technologies, Inc.

Other

Battelle Memorial Institute

The University of North Carolina at Chapel Hill

Micell Medtech Inc.

Bha Group, Inc.

Mt Acquisition Holdings LLC

James B McClain

James P DeYoung

Timothy J Romack

Charles Douglas Taylor

David E Brainard

Stephen M Gross

Joseph M DeSimone

Michael E Cole

John M Neet

Steve Worm

Gary C Schrebe

Douglas Taylor

Mark Wagner

Clint Smoke

Mike Cole

Joseph Desimone

Doug Taylor

Gina M Stewart

Ramone D Givens

Kenneth Grakauskas

Brett G Zani

John L Fulton

Clement R Yonker

David F Cauble, Jr

C Douglas Taylor

Douglas E Betts

Robert A Rabiner

Steven Lee Worm

Dean W Matson

George S Deverman

Timothy Charles Kiorpes

T Mark McCleskey

Eva Rachel Birnbaum

William Tumas

Robert John Klare

Wenda C Carlyle

Barbara J Tarasevich

R Bradley Lienhart

Wendy J Shaw

Kimberly R Powell

Kenneth L Huggins

Joseph M Crowley

Ruben Guillermo Carbonell

David Enscore

Leonard S Fifield

Bernadette Storey-Laubach

Krys Wallace

Stephanie A Crette

Arthur J Benvenuto

Meagan M Fagan

Steve L Worm

David F Cauble

Ed Dickinson

Edward Schmitt

Robert Steven Burgermeister

A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.

Polymer coatings containing drug powder of controlled morphology

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.

Drug delivery medical device

A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.

Coatings containing multiple drugs

A method for preparing a laminate coronary stent comprising: providing a stent framework; and depositing a plurality of layers on said stent framework to form said laminate coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer.

Stents having biodegradable layers

Stent delivery systems having improved deliverability comprising an elongate member having an inflation lumen and a guidewire lumen therein; a balloon having an interior that is in fluid communication with the inflation lumen; and a stent comprising a coating mounted on the balloon. Methods for making stent delivery systems having improved deliverability. Methods for delivering two stent delivery systems concurrently through a guiding catheter, each stent delivery system comprising elongate member having an inflation lumen and a guidewire lumen therein, a balloon having an interior that is in fluid communication with the inflation lumen, and a stent comprising a coating mounted on the balloon. Stent coatings may comprise a pharmaceutical agent at least a portion of which is in crystalline form.

Stent and stent delivery system with improved deliverability

A bioabsorbable biomedical implant is disclosed. The implant includes a tubular scaffold comprising a plurality of interconnected polymer struts. The interconnected polymer struts defines a plurality of deformable cells. The polymer struts have an average thickness of no more than 120 &#x3bc;m. Methods for making the bioabsorbable biomedical implant, including the methods for making the polymer materials for the tubular scaffold, are also disclosed.

Bioabsorbable biomedical implants

A coated coronary stent, comprising a stainless steel sent framework coated with a primer layer of Parylene C, and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.

Stent with polymer coating containing amorphous rapamycin

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.

Provided herein is a coated coronary stent, comprising: a. stent; b. a plurality of layers deposited on said stent to form said coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.

Coated stents

A system and method are disclosed for coating surfaces of expandable medical devices with composite coatings. Coatings are composed of various materials including, e.g., polymers and drugs. Transfer of the coatings within a patient or other host forms a drug-eluting coating that delivers time-released drugs over time for treatment of a medical condition.

System and process for formation of a time-released, drug-eluting transferable coating

Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.

Stents having bioabsorable layers

Growing community of inventors

Raleigh, NC, United States of America

James B McClain